FindTrial
Sign In

To study the molecular mechanism of Anmeidan in preventing insomnia based on the regulation of astrocytes

To study the molecular mechanism of Anmeidan in preventing insomnia based on the regulation of astrocytes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400079480
Enrollment
Unknown
Registered
2024-01-04
Start date
2024-02-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insomnia

Interventions

Anmeidan
:The serum was detected by ELISA
placebo:The serum was detected by ELISA

Sponsors

Hubei Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Clinical observation of randomized double-blind placebo-controlled trial of Anxudan was completed, and serum was retained.

Exclusion criteria

Exclusion criteria: NO

Design outcomes

Primary

MeasureTime frame
Neurotrophic factor;—

Secondary

MeasureTime frame
irisin;—

Countries

China

Contacts

Public ContactJi Ke

Hubei Hospital of Traditional Chinese Medicine

1302310092@qq.com+86 150 7137 3553

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026